The molecular defect responsible for a dramatic prolongation of all standard clotting tests discovered in a 15-yr-old boy has been identified. Initial investigations revealed the presence of an activated Factor X (Factor Xa) and thrombin inhibitor which copurified with alpha 1-antitrypsin (alpha 1-AT), thereby suggesting the occurrence of an alpha 1-AT variant similar to alpha 1-AT Pittsburgh. This was confirmed by dot-blot analysis and direct sequencing after amplification by the polymerase chain reaction. A G to T transition at nucleotide 10038 results in the substitution of Met to an Arg, converting alpha 1-AT into an Arg-Ser protease inhibitor (serpin) that inhibited thrombin and Factor Xa more effectively than antithrombin III. Surprisingly, there was no bleeding history in the proband. The common mutation Z, which may explain a reduced expression of the allele bearing the Arg 358 Met mutation, was not observed in the propositus' DNA. To exclude the presence of another mutation, the coding regions and intron/exon junctions were sequenced. No other mutation was found. Recently, the patient experienced his first hemorrhagic episode at the age of 17. The level of the abnormal inhibitor had increased twofold 2 mo before. The large decrease in protein C concentration may account for the mild bleeding tendency in this case, despite the presence of the alpha 1-AT Pittsburgh mutation. This was confirmed by dot-blot analysis and direct sequencing after amplification by the polymerase chain reaction. A G to T transition at nucleotide 10038 results in the substitution of Met to an Arg, converting a,-AT into an Arg-Ser protease inhibitor (serpin) that inhibited thrombin and Factor Xa more effectively than antithrombin III. Surprisingly, there was no bleeding history in the proband. The common mutation Z, which may explain a reduced expression of the allele bearing the Arg 358 Met mutation, was not observed in the propositus' DNA. To exclude the presence of another mutation, the coding regions and intron/exon junctions were sequenced. No other mutation was found. Recently, the patient experienced his first hemorrhagic episode at the age of 17. The level ofthe abnormal inhibitor had increased twofold 2 mo before. The large decrease in protein C concentration may account for the mild bleeding tendency in this case, despite the presence of the a,-AT Pittsburgh mutation. An abnormal protein C pattern was observed in patient's plasma, suggesting that the circulating deficiency might be due to a deleterious effect of the abnormal inhibitor on both intracellular processing and catabolism of protein C. (J. Clin.
Introduction
In 1983, a molecular defect responsible for the development of a potent circulating antithrombin activity in a young boy with a severe bleeding disorder was characterized as Met 358 to Arg substitution at the reactive Met-Ser site of alpha1-antitrypsin (a,-AT),' thereby modifying the target of this protease inhibi- Receivedfor publication 20 June 1991 and in revisedform 14 January 1992.
1. Abbreviations used in this paper: a,-AT, a1-antitrypsin; a, M, nornal ASO probe; a, N, wild-type ASO probe; a, P, mutant probe; a, Z, mutant ASO probe; ASO, allele-specific oligonucleotide; AT III, antithrombin III; Factor Xa, activated Factor X; PCR, polymerase chain reaction.
tor (1) . This mutant, designated a,-AT Pittsburgh, or recombinant Arg 358 a,-AT, was shown to inhibit other clotting proteases (2) (3) (4) , thus displaying strong functional analogy with the physiologic clotting inhibitor antithrombin III (AT III), whose reactive site consists of an Arg-Ser bond. This mutation provided an explanation for the patient's recurrent and ultimately fatal hemorrhagic diathesis (1, 5) , and confirmed the critical role played by a single amino acid at the reactive site of serineprotease inhibitors (serpins). Serpins are a superfamily of proteins that have evolved from a primitive ancestral inhibitor and to which a,-AT and AT III both belong (6) .
Recently, a,-AT was described as a physiological inhibitor of activated protein C (7), a natural anticoagulant playing a major role in the regulation of blood coagulation (for review see 8) . Moreover, the Met 358 to Arg substitution was shown to multiply by 4,400 the rate ofactivated protein C inhibition (9) . A protease responsible for the intracellular processing of precursor polypeptides is also inhibited by the mutated a,-AT (10) . Its coexpression with complement C3 and albumin in transfected cells led to the inhibition of propeptide cleavage ( 11) . Such an inhibition confirmed the mechanism proposed to explain the presence of proalbumin in the Pittsburgh patient's plasma (12) . We suspected the presence of a similar abnormality in a 15-yr-old patient whose routine tests before surgery revealed markedly impaired coagulation, and were able to confirm the existence ofa Met 358 to Arg mutation by genomic DNA analysis. This patient had, however, never experienced any hemorrhagic complication. The association of the a,-AT mutation with a profound decrease in plasma protein C concentration suggests that Arg 358 a1-AT interferes with the in vivo metabolism of this anticoagulant regulatory protein.
Methods
Coagulation factor assays. All plasma clotting assays were performed using commercial reagents from Diagnostica Stago (Gennevilliers, France) for Factors XII, XI, IX, VIII, X, and VII, or from bioMerieux (Lyon, France) for Factors II and V.
Protein C was evaluated by amidolytic assays after Protac activation (Diagnostica Stago), and after thrombin activation of an aluminium hydroxide eluate according to Bertina (13) , using Coatest protein C (Kabi, Mohndal, Sweden). AT III was measured using an amidolytic assay (AT-prest, Diagnostica Stago). Fibrinogen was evaluated in a chronometric assay, using Fibrinogen kit from bioMerieux.
Immunoassays were performed using immune sera from Diagnostica Stago and rocket immunoelectrophoresis, except for protein C and Factor VII, which were measured by immunoenzymatic techniques (Diagnostica Stago).
Bleeding time was measured using a simplate device (Organon Teknika, Turnhout, Belgium).
Purification of the variant. Plasma from the patient was first ad- (13) .
Results
Case report. The hemostatic abnormality was discovered during a routine preoperative laboratory investigation of a 1 5-yrold-boy suffering from kyphoscoliosis. The patient had no personal or family history of spontaneous bleeding. Moreover, a traumatic humeral fracture sustained at the age of 12 was not associated with any bleeding complication. Apart from orthopedic disease, his clinical examination was entirely normal.
Laboratory evaluation included immunoelectrophoresis, complement, tumoral markers, antinuclear factors, immune complexes, blood and urinary amino acids, and bone marrow aspirate, all ofwhich were normal. No hematuria was detected. Chest x-ray, abdominal echography, bone scintigraphy, and abdominal and thoracic CAT scan were also normal.
The results of the coagulation tests (Table I) suggested the presence of a potent coagulation inhibitor, because they showed no correction by mixing with normal plasma. Coagulation Factors XII, XI, IX, and VIII all had activities ofless than 10%. The activities ofFactors II, V, VII, and X were 40,65,42, and 17%, respectively. Protein S, AT III, and fibrinogen were within the normal range. Bleeding time was 1O min (normal values < 9 min).
Protein C activity, measured in plasma by an amidolytic assay after activation by Protac, was less than 10%. In aluminium hydroxide eluates, protein C amidolytic activity measured after activation by thrombin according to Bertina (13) was 18%.
The concentrations of some ofthe factors measured by immunoassays were normal or slightly reduced (Factor II: 50%; V: 75%; X: 46%; IX: 72%; VII: 70%). The protein C antigen concentration, measured on several plasma dilutions, was greatly reduced to 13% of normal values.
The parents and siblings of the propositus all had normal protein C and clotting factor concentrations in both the activity and immunologic assays (not shown).
The patient came 19 mo later (June 1991) for a routine clinical examination. Laboratory investigations showed the same coagulation profile with a protein C concentration of 26%. During August 1991, he went to an Eastern European country for vacation. He suddenly suffered from swelling and pain in the right buttock. An intramuscular injection of an unidentified drug was performed. 4 d later, he was hospitalized in our department. His coagulation factors were similar to the levels previously observed, including protein C concentration which was 18% of normal value. A CAT scan confirmed the diagnosis of buttock hematoma measuring 20 x 8 cm. After two plasmapheresis of 3 liters, the hematoma was operated on and drained without any complication. (Fig. 3) .
Frozen plasma from the original Pittsburgh patient, obtained by plasma exchange at the time of the ultimate hemorrhagic episode, presented standard coagulation tests similar to those observed at the time ofsampling. This suggests that most protein activities were unaffected by prolonged storage. The protein C level using the immuno-enzymatic technique was 62%. The abnormal inhibitor concentration, evaluated by the rate of thrombin inhibition as described above, was 42 puM.
Genomic DNA analysis. Molecular characterization of the a,-AT Pittsburgh abnormality, i.e., a Met 358 to Arg mutation, was performed on amplified exon V, which encoded for the al-AT reactive site, using dot-blot analysis and direct sequencing. In an attempt to explain the reduced expression of the mutant gene product, we also searched for a mutation frequently involved in quantitative deficiencies in Caucasians: the Z mutation, also located in exon V. The conversion ofMet 358 to Arg requires substitution ofa G for T at position 10038 of the a,-AT gene in the numbering system ofLong et al. (14) . The specific wild-type ASO probe (a, N) and the mutant probe (al P) were synthesized in accordance with this change, and the samples were hybridized with both a1I N and al P. We also analyzed the amplified DNA with the corresponding normal and mutant ASO probes (al M and al Z) (19) , with the Z mutation in the same exon at position 9991 (G to A substitution). A schematic representation ofthe al-AT exon V with the positions of the different PCR primers and ASO probes is shown in Fig. 4 . The pedigree of the patient's family and the complete results ofexon V analysis are displayed in Fig. 5 . Only DNA from No amplified DNA hybridized with the mutant a, Z ASO probe, demonstrating that the propositus and members of his family exhibited a normal homozygous M genotype.
To confirm the dot-blot results and search for another putative mutation in this part ofthe aI -AT gene, we determined the nucleotide sequence ofexon V after single-strand PCR amplification between primers a, A and al B, using a, A for the sequencing reaction. The results (Fig. 6) show that our patient bears a heterozygous G to T substitution at position 10038 that generates an AGG codon instead ofan ATG codon at position 358 of the mature protein. No other nucleotide substitution was observed in exon V.
Furthermore, all the coding regions of the a, AT gene, as well as the intron/exon junctions, were sequenced after asymmetric PCR, as described in Methods, using the oligonucleotides listed in Table III . No other mutation was found.
SDS-PAGE and immunoblot analysis of protein C. As stated in the case report, a decrease in the concentration of several vitamin K-dependent factors was observed in our patient. The extremely low level of protein C was of particular interest, as it may provide an explanation for the mild hemorrhagic tendency. As a defect in the expression of one or both alleles encoding for protein C was extremely unlikely, we suspected that the a,-AT mutant was the cause of the defect, and therefore analyzed patient's plasma for the presence of abnormal forms of protein C. The blots for protein C antigen obtained from 10% and 7% SDS-PAGEs clearly showed an abnormal migration in the plasma obtained from our patient, or from the original Pittsburgh case (Fig. 7) . In normal plasma, protein C migrates as a triplet, as described (20), with molecular masses of 68, 58, and 54 kD, respectively, due to variations in the carbohydrate chains (21). Patient's plasma yielded a single band at 68 kD, and another compound migrating as a doublet with a mass of 97 and 102 kD. This abnormal pattern was also observed in the original Pittsburgh case. In normal plasma, activation by Protac led to the appearance of a high molecular mass compound which probably results from the formation of complexes between activated protein C and its two inhibitors, protein C inhibitor and a,-AT (22, 23) . Activation of our patient's plasma resulted in an almost complete disappearance of the 68-kD band. The activated protein C-inhibitor complexes, if formed, could not be distinguished from the 97-kD compound observed before activation.
To investigate whether the high molecular mass bands resulted from complex formation between activated protein C and the mutated a,-AT, we made additional experiment on semipurified samples obtained from plasma processed by aluminum hydroxide adsorption (Fig. 8) . Vitamin K-dependent zymogens normally bind to aluminum hydroxide, and thus can be separated from the physiologic inhibitors that remain in the supernatant. Protein C eluates prepared from normal plasmas were activated by Protac and added to the purified abnormal inhibitor. High molecular mass complexes of 98 and 105 kD were formed, confirming a strong inhibitory effect of the (Fig. 8 A) . When protein C eluates were prepared from the patient's plasma, high molecular mass complexes were observed in the absence of any additional components (Fig. 8 B) .
One of them (arrow 1) reacted with both protein C and a,-AT antisera. These data strongly suggest the presence in the patient's circulation ofactivated protein C-Ga-AT Pittsburgh complexes.
Discussion
Screening tests performed in a 15-yr-old patient with abnormal coagulation tests revealed the presence of a strong coagulation inhibitor. The abnormal inhibitor copurified with a,-AT and presented several characteristics of the mutated protein called a,-AT Pittsburgh. The identification of this mutation was initially done when the patient had no bleeding history. 22 mo later, he experienced a first bleeding episode.
Direct sequencing of amplified DNA allowed us to rapidly identify a G to T substitution in exon V of the a1-AT gene encoding for the reactive site ofthe serpin in this second case of aI-AT Pittsburgh variant. Both parents of our patient had normal DNA sequence for exon V, which suggests the existence of a spontaneous mutation during gamete formation in one ofthe genitors or during the first steps of embryogenesis.
This conversion ofa Met serpin to an Arg serpin resulted in marked inhibition ofthrombin and Factor Xa. These proteases were both inhibited by the variant protein purified from our patient's plasma, with second-order constant rates similar to those observed for the first a1-AT Pittsburgh variant (2) .
Other coagulation factors were found to have markedly reduced activities in clotting assays performed with the patient's plasma, probably due to the presence of the mutant inhibitor. The virtual absence of protein C activity from the patient's plasma might have been due to the strong inhibitory activity of Arg 358 a,-AT toward activated protein C in vitro (9) . However, this does not explain the markedly reduced activity of protein C measured in the absence of inhibitors, according to Bertina (13) , or the reduced concentration observed ex vivo with an immunoenzymatic assay. As the patient's parents had normal protein C antigen, a homozygous deficiency can be excluded. The immunologic concentration of two other vitamin K-dependent zymogens (Factors X and II) were also decreased, but to a lesser extent.
The presence of abnormal molecular forms of protein C in our patient's plasma, as well as in the plasma provided to us from the original Pittsburgh case, suggests that this mutation of a,-AT has unexpected effects on protein C metabolism. The 68-kD compound might be uncompletely processed protein C, and the high molecular weight compounds that reacted with a1-AT immune serum probably reflect the presence of activated protein C-Arg 358 a,-AT complexes in the circulation.
As the mutant a I-AT Pittsburgh has a strong affinity for thrombin, it should block protein C activation within the circulation. However, the in vivo activation is mediated by thrombin bound to thrombomodulin at the vascular endothelium surface (24, 25) , which may reduce the affinity of the enzyme for the mutated inhibitor and makes possible the activation ofprotein C. The presence of proalbumin in the original Pittsburgh case (also observed in our patient) was shown to be due to an inhibitory effect of the a,-AT variant on propeptide cleavage (12) . Protein C undergoes several intracellular modifications, including endoproteolytic processing to remove the propeptide and the dipeptide that connect the heavy and light chains in the precursor (26, 27 ). An inhibition of the endoprocessing might reduce the secretion of protein C in the extracellular medium. The removal of protein C from the circulation may also be accelerated by the rapid formation of complexes with the mutated a,-AT.
Comparison of the present case with the original case of a,-AT Pittsburgh shows a strong discrepancy in the clinical expression of the mutation. The first patient died at the age of 14 after more than 50 episodes of bleeding in an acute-phase state, while our patient displayed a mild bleeding tendency with a first episode at the age of 17. The protein C deficiency observed in our patient might explain the maintenance of the in vivo hemostatic balance. Since the importance of protein C as a physiologic inhibitor has only been known since 1981 (28), protein C was not measured when the first Pittsburgh variant case was reported in 1978 (5) . In a plasma kept frozen for more than 10 yr, we found the same abnormal molecular forms of protein C as those observed in our patient. The protein C level at the lower limit of the normal range (62%) does not allow conclusion, as the assay was performed on a single sample kept frozen for a long time. As the a,-AT gene is pleiomorphic (29, 30) , our first hypothesis to explain why our patient was asymptomatic was the presence on the same allele of a second mutation leading to a reduced expression of the gene. We used dotblot analysis with ASO probes to exclude the presence ofthe Z mutation frequently observed in Caucasians. We also analyzed the a,-AT genomic DNA coding sequences and intron/exon junctions, and did not find an additional mutation that could explain the reduced amount of mutated protein initially oW served in our patient. 
